Potential Uses of Soliris®
A Panel Discussion Among Six Immunologists and Basic Science Researchers
Panel Intelligence, LLC
Deliverable: Transcript with key findings
Study Description and Objectives
Panel Intelligence conducted an online panel discussion among six immunologists and other basic science researchers about Soliris® (eculizumab) and its potential uses to treat diseases other than paroxysmal nocturnal hemoglobinuria (PNH). Secondary objectives of this study included the following:
§ Discuss what is known about Soliris including its:
· Strengths and weaknesses
· Mechanism of action
§ Identify other diseases aside from PNH for which Soliris can be used as treatment
§ Explore the potential use of Soliris in the treatment of:
· Myasthenia gravis
· Multifocal motor encephalopathy
· Miller Fisher Syndrome variant of Guillain-Barre Syndrome
· Membranous nephropathy
· Dense deposit disease
· Lupus nephritis
· Rheumatoid arthritis
· Dermatomyositis
· Age-related macular degeneration
|
Company |
Ticker Symbol |
Product(s) |
|
Alexion Pharmaceuticals |
ALXN |
Soliris® (eculizumab) |
Inclusion Criteria and Panel Details
|
Inclusion Criteria |
§ Immunologist or basic science researcher studying the complement cascade and any diseases related to it § US-based and international panel § Currently studying the complement cascade and any diseases related to its dysfunction § Familiar with Soliris® (eculizumab) § Not involved in any clinical trials for Soliris® (eculizumab) and not a consultant/advisory board member/speaker for Alexion Pharmaceuticals |
|
Discussion Dates |
January 9, 2009 through January 28, 2009 |
|
Institution |
Location |
|
|
TX |
|
|
NY |
|
|
SC |
|
|
France |
|
|
PA |
|
University of |
TX |
Print Abstract
For additional information on this study or to purchase, please call:
|
Discussion
Other |